Alan Pollack, MD, PhD, on Prostate Cancer: Postprostatectomy Radiotherapy
2016 ASTRO Annual Meeting
Alan Pollack, MD, PhD, of the University of Miami Health System, summarizes a session that included discussion of outcomes, dose response, oligometastatic disease, and gene predictor of response. (Presentations 228-235)
Richard T. Hoppe, MD, of Stanford University, summarizes a session on improving outcomes by enhancing old and new indications in follicular lymphoma and Hodgkin lymphoma. (Scientific Session 5)
Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate-risk prostate cancer. (Abstract LBA-5)
Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)
Douglas W. Arthur, MD, of Virginia Commonwealth University, discusses the 3-year efficacy report from a phase II study of repeat breast-preserving surgery and 3D conformal partial breast reirradiation for in-breast recurrence. (Abstract LBA-10)
Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)